Therapeutic areas

Our infectious diseases portfolio is the broadest in the industry and, including HIV, accounts for two thirds of our pipeline.

We are leaders in HIV, focused on ending the global epidemic. We have an industry-leading pipeline, driven by patient insights.

We are pushing the frontiers of respiratory science and harnessing the science of the immune system to transform patient outcomes in areas of unmet need, based on decades of innovative research.

Our emerging oncology portfolio is focused on seeking solutions for blood and gynaecologic cancers and making breakthroughs in immuno-oncology and tumour-cell targeting therapies.